Katja Fink

Dr. Katja Fink joined ImmunoScape with over 20 years of experience in basic and applied immunology research. As the Senior Director of ImmunoScape’s Hit Discovery program in Singapore, she leads the company’s efforts to identify tumor-specific T cells and T cell receptors that are therapeutically relevant and can be developed into immunotherapies for cancer.

Prior to joining ImmunoScape, Dr. Fink served as the Director, Antibody Research at Humabs BioMed SA in Switzerland, a subsidiary of Vir Biotechnology, San Francisco, where she coordinated and guided the discovery and pre-clinical development of therapeutic antibodies to infectious diseases including SARS-CoV-2.

Earlier in her career, she established a research group at the Singapore Immunology Network at A STAR that successfully discovered and developed new approaches for dengue vaccines, therapeutic antibodies, and disease biomarkers. Dr. Fink has published over 65 original research articles in peer-reviewed journals including Science, Nature, and Cell. She holds an M.S. in Biochemistry from the University of Zurich and a PhD in Immunology from the ETH in Zurich, Switzerland.